期刊文献+

感染性休克患者血管加压素血浆浓度及临床相关因素的分析 被引量:3

下载PDF
导出
摘要 感染性休克患者常存在顽固性低血压及儿茶酚胺类药物抵抗现象,导致其治疗困难及高死亡率。理论上,在感染性休克患者中血管加压素(arginine-vasopressin,AVP)能发挥有效的缩血管作用。
出处 《临床麻醉学杂志》 CAS CSCD 北大核心 2011年第9期921-922,共2页 Journal of Clinical Anesthesiology
  • 相关文献

参考文献6

  • 1Leone M, Albanese J, Delmas A, et al. Terlipressin in cate- cholamine resistant septic shock patients. Shock, 2004, 22: 314-319.
  • 2Mutlu GM, Factor P. Role of vasopressin in the management of septic shock. Intensive Care Med, 2004, 30: 1276-1291.
  • 3Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med, 2008, 358:877- 887.
  • 4Maxime V, Siami S, Annane D. Metabolism modulators in sepsis: the abnormal pituitary response. Crit Care Med, 2007, 35: S596-601.
  • 5O' Brien AJ, Thakur G, Buckley JF, et al. The pore-forming subunit of the K(ATP) channel is an important molecular tar- get for LPS-induced vascular hyporeactivity in vitro. Br J Pharmacol, 2005, 144:367 -375.
  • 6周晓敏,薛张纲,葛圣金.小剂量精氨酸加压素在血管扩张性休克病人中的应用[J].临床麻醉学杂志,2007,23(11):885-887. 被引量:1

二级参考文献7

  • 1Malay MB, Ashton JL, Dahl K, et al. Heterogeneity of the vasoconstrictor effect of vasopressin in septic shock. Crit Care Med, 2004,32:1327-1331.
  • 2Holmes CL, Patel BM, Russell JA, et al. Physiology of vasopressin relevant to management of septic shock. Chest, 2001,120: 989-1002.
  • 3Mutlu GM, Factor P. Role of vasopressin in the management of septic shock. Intensive Care Med, 2004,30 : 1276-1291.
  • 4Jochberger S, Mayr VD, Luckner G, et al. Serum vasopressin concentrations in critically ill patients. Crit Care Med, 2006,34 : 293-299.
  • 5Dunser MW, Mayr AJ, Tur A, et al. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamineresistant vasodilatory shock: incidence and risk factors. Crit Care Med, 2003,31 : 1394-1398.
  • 6Wiesenac kC, Prasser C, Rodig G, et alo Stroke volume variation as an indicator of fluid responsiveness using pulse contour analysis in mechanically ventilated patients. Anesth Analg, 2003,96: 1254-1257.
  • 7王毅伟,朱玉琦,赵金英,林世升,张利军.失血性休克患者血浆肾上腺髓质素与血管阻力变化的关系[J].临床麻醉学杂志,2002,18(5):248-249. 被引量:3

同被引文献30

  • 1赵会新,乔宠,高嵩,王永来.腹腔镜下子宫肌壁间肌瘤核除术中应用垂体后叶素的临床效果分析[J].实用药物与临床,2007,10(2):69-70. 被引量:20
  • 2Kamisago M,Sharma SD,DePalma SR,Solomon S,Sharma P,McDonough B,et al.Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy[J].N Engl J Med,2000,343:1 688-1 696.
  • 3Morimoto S.Sarcomeric proteins and inherited cardiomyopathies[J].Cardiovasc Res,2008,77:659-666.
  • 4Sahn DJ,Demaria A,Kisslo J,et al.Recommendations regarding quantitation inM-modeechocardiography:results of asurvey of echocardiographicmeasurements[J].Circulation,1978,58:1 072.
  • 5OcBrien AJ,Thakur G,Buckley JF,et al.Thepore-forming subunit of theK (ATP) channelis animportant molecular tar-get for LPS-induced vascular hyporeactivity in vitro[J].Br J Pharmacol,2005,144:367-375.
  • 6Nguyen T,Pei R,Landry DW,et al.Microfluidic aptameric affinity sensing of vasopressin for clinical diagnostic and therapeutic applications[J].Sensors and Actuators B Chemical,2011,154(1):59-66.
  • 7Bauer SR,Culver DA,Abraham S,et al.Detectability of vasopressin in continuous venovenous hemodialysis effluent of patients with vasodilatory shock treated with exogenous arginine vasopressin.[J].Pharmacotherapy,2011,31(9):857-862.
  • 8Treschan TA.Peters J.The vasopressin System:physiology and clinical strategies[J].Anesthesiology,2006,105(3):599-612.
  • 9王美兰,顾平,陶海燕,陆玉梅,张琳.垂体后叶素在难治性感染性休克中应用的护理[J].中华护理杂志,2008,43(10):904-905. 被引量:5
  • 10邓振忠,赵允召.去甲肾上腺素在脓毒症休克中的应用进展[J].医学研究生学报,2009,22(3):311-314. 被引量:7

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部